Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,277.51 +42.03 (+0.80%) Dow
38,686.32 +574.82 (+1.51%) Nasdaq
16,735.02 -2.08 (-0.01%) Bitcoin USD
69,128.82 +1,060.34 (+1.56%) CMC Crypto 200
1,488.88 +20.94 (+1.43%)
KPTI Aug 2024 2.500 put
| Previous close | 1.3900 |
| Open | 1.3900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expiry date | 2024-08-16 |
| Day's range | 1.3900 - 1.3900 |
| Contract range | N/A |
| Volume | |
| Open interest | 34 |
PR NewswireKaryopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated exploratory subgroup analyses from the SIENDO study (NCT03555422), in patients with advanced or recurrent TP53 wild-type endometrial cancer at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The data were presented in a special ASCO plenary series rapid abstract update session on June 1 at 12:30pm CT and simult
- PR Newswire
Karyopharm to Participate at the Jefferies Global Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m. ET in New York, NY.
Simply Wall St.Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Karyopharm Therapeutics ( NASDAQ:KPTI ) First Quarter 2024 Results Key Financial Results Revenue: US$33.1m (down 14...
